NI
58
-5
MDT
62
3
EXR
46
-2
XYL
33
-4
HON
58
3
LH
40
-2
AMGN
39
-2
IRM
63
-2
M
28
-3
KIM
66
2
TGNA
35
-2
CMS
54
-4
PVH
57
2
A
41
7
DG
23
2
CI
52
7
CAH
47
15
EXPE
72
2
GPC
22
-3
CMG
63
9
NI
58
-5
MDT
62
3
EXR
46
-2
XYL
33
-4
HON
58
3
LH
40
-2
AMGN
39
-2
IRM
63
-2
M
28
-3
KIM
66
2
TGNA
35
-2
CMS
54
-4
PVH
57
2
A
41
7
DG
23
2
CI
52
7
CAH
47
15
EXPE
72
2
GPC
22
-3
CMG
63
9
Financhill
Back

Stereotaxis 10K Form

Sell
34

STXS
Stereotaxis

Last Price:
1.94
Seasonality Move:
4.4%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive STXS News And Ratings

See the #1 stock for the next 7 days that we like better than STXS

STXS Financial Statistics

Sales & Book Value

Annual Sales: $26.77M
Cash Flow: $-3.11M
Price / Cash Flow: 0
Annual Sales: $0.14
Price / Book: 14.46

Profitability

EPS (TTM): -0.26000
Net Income (TTM): $-20.75M
Gross Margin: $14.86M
Return on Equity: -94.33%
Return on Assets: -49.35%

Stereotaxis Earnings Forecast

Key Stereotaxis Financial Ratios

  • The Gross Profit Margin over the past 24 years for STXS is 55.51%.
  • The Selling, General & Administrative Expenses for STXS have been equal to 98.71% of Gross Profit Margin.
  • The Research & Development expenses have been 38.37% of Revenue.
  • The Interest Expense is 16.67% of Operating Income.
  • The Net Earning history of STXS is -77.37% of Total Revenues.
  • Per Share Earnings over the last 24 years have been positive in 13 years.

Stereotaxis Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Health Care Equipment & Supplies
Sector: Health Care
Current Symbol: STXS
CUSIP: 85916J
Website: stereotaxis.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 2.29
Quick Ratio: 1.43

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

STXS Technical Analysis vs Fundamental Analysis

Sell
34
Stereotaxis (STXS) is a Sell

Is Stereotaxis a Buy or a Sell?

  • Stereotaxis stock is rated a Sell
    The current Stereotaxis [STXS] share price is $1.94. The Score for STXS is 34, which is 32% below its historic median score of 50, and infers higher risk than normal.